Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure

Kidney International

Volumn 75, Issue 6, 2009, Pages 617-625

  Lomashvili, Koba A ^a   Monier Faugere, Marie Claude ^b   Wang, Xiaonan ^a   Malluche, Hartmut H ^b   O'Neill, W Charles ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Bone formation; Bone histomorphometry; Bone resorption; Pyrophosphate; Rat aorta; Uremic osteodystrophy

Indexed keywords

ETIDRONIC ACID; HYDROXYAPATITE; PAMIDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CALCIFICATION; ARTICLE; BONE MINERALIZATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; MALE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PHOSPHATE INTAKE; PRIORITY JOURNAL; RAT; UREMIA;

ANIMALS; AORTIC DISEASES; BONE AND BONES; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; CALCINOSIS; DIPHOSPHONATES; ETIDRONIC ACID; RATS; UREMIA;

EID: 61349180704     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.646     Document Type: Article

References (37)

1. O'Neill WC. Vascular calcification: not so crystal clear. Kidney Int 2007; 71: 282-283.
2. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95: 560-567.
3. Min H, Morony S, Sarosi I et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192: 463-474.
4. Russell RGG, Bisaz S, Fleisch H. Pyrophosphate and diphosphates in calcium metabolism and their possible role in renal failure. Arch Intern Med 1969; 124: 571-575.
5. Meyer JL. Can biological calcification occur in the presence of pyrophosphate? Arch Biochem Biophys 1984; 231: 1-8.
6. Francis MD, Russell RGG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathologic calcification in vivo. Science 1969; 165: 1264-1266.
7. Lomashvili KA, Cobbs S, Hennigar RA et al. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004; 15: 1392-1401.
8. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005; 16: 2495-2500.
9. Lomashvili KA, Garg P, Narisawa S et al. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int 2008; 73: 1024-1030.
10. Goding JW. Ecto-enzymes: physiology meets pathology. J Leukocyte Biol 2000; 67: 285-308.
11. Belli SI, van Driel IR, Goding JW. Identification and characterization of a soluble form of the plasma cell membrane glycoprotein PC-1 (5′-nucleotide phosphodiesterase). Euro J Biochem 1993; 217: 421-428.
12. Goding JW, Terkeltaub RA, Maurice M et al. Ecto-phosphodiesterase/ pyrophosphatase of lymphocytes and non-lymphoid cells: structure and function of the PC-1 family. Immunological Reviews 1998; 161: 11-26.
13. 3 in rats. Clin Sci 1968; 35: 363-372.
14. Fleisch H, Russell RGG, Bisaz S et al. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Euro J Clin Invest 1970; 1: 12-18.
15. Fleisch H. Bisphosphonates: mechanisms of action. Endocrine Rev 1998; 19: 80-100.
16. Potokar M, Schmidt-Dunker M. The inhibitory effect of new diphosphonic acids on aortic and kidney calcification in vivo. Atherosclerosis 1978; 30: 313-320.
17. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21: 817-824.
18. Price PA, Roublick AM, Williamson MK. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 2006; 70: 1577-1583.
19. Saito E, Wachi H, Sato F et al. Treatment with vitamin K2 combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells. J Atheroscler Thromb 2007; 14: 317-324.
20. Vaisman DN, McCarthy AD, Cortizo AM. Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. Biol Trace Elem Res 2005; 104: 131-140.
21. Geng Z, Monier-Faugere M-C, Bauss F et al. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin Nephrol 2000; 54: 45-53.
22. Markowitz GS, Fine PL, Stack JI et al. Toxic acute tubular necrosis following treatment with zolendonate (Zometa). Kidney Int 2003; 64: 281-289.
23. Van Beek E, Hoekstra M, Van de Ruit M et al. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 1994; 9: 1875-1882.
24. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tiss Res 1973; 11: 269-280.
25. Kaufman HW, Kleinberg I. Studies on the incongruent solubility of hydroxyapatite. Calcif Tissue Int 1979; 27: 143-151.
26. Neuman WF, Neuman MW. The chemical dynamics of bone mineral. University of Chicago Press, Chicago, 1958.
27. Evans JR, Robertson WG, Morgan DB et al. Effects of pyrophosphate and diphosphonates on the dissolution of hydroxyapatites using a flow system. Calcif Tissue Int 1980; 31: 153-159.
28. Murshed M, Harmey D, Millan JL et al. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Development 2006; 19: 1093-1104.
29. Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature 1997; 386: 78-81.
30. Wada T, McKee MD, Steitz S et al. Calcification of vascular smooth muscle cell cultures. Inhibition by osteopontin. Circ Res 1999; 84: 166-178.
31. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineagemarkers. Circ Res 2001; 89: 1147-1154.
32. Yokozawa T, Zheng PD, Oura H et al. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986; 44: 230-234.
33. Okada H, Kaneko Y, Yawata T et al. Reversibility of adenine-induced renal failure in rats. Clin Exper Nephrol 1999; 3: 82-88.
34. Moorehead WR, Biggs HG. 2-amino-2-methyl-1-propanol as the alkalizing agent in an improved continuous-flow cresolphthalein complexone procedure for calcium in serum. Clin Chem 1974; 20: 1458-1460.
35. Cogan EB, Birrell GB, Griffith OH. A robotics-based automated assay for inorganic and organic phosphates. Anal Bioch 1999; 271: 29-35.
36. Malluche HH, Sherman D, Meyer W et al. A new semiautomatic method for quantitative static and dynamic bone histology. Calcif Tissue Int 1982; 34: 439-448.
37. Manaka RC, Malluche HH. A program package for quantitative analysis of histologic structure and remodeling dynamics of bone. Comput Programs Biomed 1981; 13: 191-202.